Effect of carbenoxolone sodium on human gastric acid secretion

J. H. BARON

From the Department of Surgery, Royal Postgraduate Medical School, London

SUMMARY Neither basal nor peak acid output changed significantly after treatment for four weeks with carbenoxolone sodium as Biogastrone tablets in patients with gastric ulcer or Duogastrone capsules in patients with duodenal ulcer.

The mechanisms of ulcer healing by carbenoxolone are not fully understood. One of the early controlled trials (Bank et al., 1967) suggested that carbenoxolone may have an inhibitory effect on gastric acid secretion, but later studies have been inconclusive (Table). This problem has, therefore, been re-examined using appropriate preparations of carbenoxolone in patients with gastric ulcer and with duodenal ulcer.

Methods

SUBJECTS
Ten patients with gastric ulcer were given carbenoxolone sodium as Biogastrone tablets 100 mg three times a day for four weeks. Ten patients with duodenal ulcer were given Duogastrone capsules 50 mg four times a day for four weeks.

TESTS
Basal and peak acid output after pentagastrin were measured by standard methods (Baron, 1963a). The patient fasted overnight and a nasogastric tube was positioned fluoroscopically in the body of the stomach. The stomach was emptied, and 15-minute collections of gastric juice were then made by continuous pump and intermittent hand suction. After a basal hour pentagastrin, 6 μg/kg was injected intramuscularly, and four further 15-minute collections were made. Volume, pH, and titratable acidity (to pH 7) were measured. Peak acid output (mmol/h) was calculated by doubling the sum of the two highest consecutive 15-minute periods of acid output after pentagastrin.

Acid tests were done before, and the morning after the end of, the four-week course of treatment with carbenoxolone. The significances of differences were calculated non-parametrically by Wilcoxon's matched-pairs signed-rank test.

Results (Figure)

The basal and peak acid outputs of the patients with gastric and duodenal ulcer were similar to those previously reported (Baron, 1963b). After treatment with carbenoxolone as Biogastrone basal acid out-

Table Effect of carbenoxolone sodium on human gastric acid secretion

<table>
<thead>
<tr>
<th>Source</th>
<th>Subjects</th>
<th>n</th>
<th>Drug</th>
<th>Dose (mg/day)</th>
<th>Duration (weeks)</th>
<th>BAO</th>
<th>PAO (reduction %)</th>
<th>Stimulant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bank et al. (1967)</td>
<td>GU</td>
<td>11</td>
<td>Biogastrone</td>
<td>300</td>
<td>1</td>
<td>24</td>
<td></td>
<td>Augmented histamine</td>
</tr>
<tr>
<td></td>
<td>GU</td>
<td>11</td>
<td>Placebo</td>
<td>200</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cocking and MacCaig (1969)</td>
<td>GU</td>
<td>16</td>
<td>Biogastrone</td>
<td>300</td>
<td>1</td>
<td>13</td>
<td></td>
<td>Augmented histamine</td>
</tr>
<tr>
<td></td>
<td>GU</td>
<td>17</td>
<td>Placebo</td>
<td>150</td>
<td>4</td>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Berstad et al. (1970)</td>
<td>DU</td>
<td>2</td>
<td>Carbenoxolone Intraduodenal</td>
<td>200</td>
<td>2 min</td>
<td>Inconstant</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Controls</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geismar et al. (1973)</td>
<td>GU</td>
<td>13</td>
<td>Biogastrone</td>
<td>300</td>
<td>1</td>
<td></td>
<td></td>
<td>Augmented histamine</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>150</td>
<td>3</td>
<td>p &lt; 0.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ottenjann and Rösch (1970)</td>
<td>GU</td>
<td>11</td>
<td>Placebo</td>
<td>300</td>
<td>1</td>
<td>NS</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Biogastrone</td>
<td>150</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baas et al. (1975)</td>
<td>Controls</td>
<td>6</td>
<td>Biogastrone</td>
<td>300</td>
<td>1</td>
<td>NS</td>
<td></td>
<td>Pentagastrin</td>
</tr>
<tr>
<td>Domshke et al. (1975)</td>
<td>Controls</td>
<td>10</td>
<td>Biogastrone</td>
<td>300</td>
<td>6 d</td>
<td>NS</td>
<td></td>
<td>Pentagastrin</td>
</tr>
<tr>
<td>Gordon et al. (1975)</td>
<td>Controls</td>
<td>6</td>
<td>Biogastrone</td>
<td>300</td>
<td>1</td>
<td>&lt;0.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>150</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

721
J. pentagastrin 200 mg/day. Basal acid output fell in patients treated with carbenoxolone.

Carbenoxolone had no significant systematic effect on basal and peak aspirated acid output, which represents the sum of acid secretion into the stomach minus pyloric loss and neutralisation by saliva and duodenal juice. Admittedly, no allowance was made in the present studies for these three errors, so that it is theoretically possible, though highly unlikely, that carbenoxolone both reduced gastric acid secretion and reduced salivation, pyloric loss, and reflux.

Conclusion

The absence in this series of any significant changes in basal or peak acid output after carbenoxolone given for four weeks to patients with gastric or duodenal ulcer makes it improbable that carbenoxolone has an inhibitory effect on gastric acid secretion, or that its ulcer-healing effect could be related to inhibition of gastric acid.

References


Effect of carbenoxolone sodium on human gastric acid secretion.

J H Baron

Gut 1977 18: 721-722
doi: 10.1136/gut.18.9.721

Updated information and services can be found at: http://gut.bmj.com/content/18/9/721

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Stomach and duodenum (1689)
Ulcer (484)

Notes